Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), sold 25,000 shares at $161.11 ($4.0M) on 2026-02-26, disclosed to the SEC on 2026-02-27.
Scheduled sale ($4.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |
| AXSM | SELL | 2025-05-20 | $322K | — | Filing → |